The American Journal of Managed Care20h
FDA Approves Isatuximab With VRd as First-Line Option for Transplant-Ineligible Multiple Myeloma
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
oncnursingnews21h
FDA Approves Isatuximab Plus VRd for Newly Diagnosed Myeloma
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
Targeted Oncology21h
FDA Approves Isatuximab Plus VRd in Transplant-Ineligible Multiple Myeloma
The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...
Targeted Oncology3d
Positive Isa-VRd Trials in Transplant-Ineligible Myeloma Show New Approach
During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for ...
Cure Today1d
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple Myeloma
The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid ...
pharmaphorum3d
Sanofi gets first OK for isatuximab for myeloma, challenging J&J’s Darzalex
Sanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming the first direct rival to Johnson & Johnson’s big-selling Darzalex.
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal ...
Pharmabiz15d
ALX Oncology doses first patients for UMBRELLA phase 1/2 study with Sanofi to evaluate evorpacept in combination with Sarclisa
South San Franciso, California Friday, September 6, 2024, 16:30 Hrs [IST] ...
Nasdaq17d
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
The Company’s pipeline of therapeutic candidates with standard-of-care agents include: About SARCLISASARCLISA (isatuximab-irfc) is a monoclonal antibody that binds to a specific epitope on the ...
National Institute for Health and Care Excellence27d
Guidance, NICE advice and quality standards In development
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981 Technology appraisal guidance TBC Isatuximab with pomalidomide and dexamethasone for treating ...